Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pyelonephritis-associated fimbriae (P-fimbriae) are hair-like surface appendages primarily expressed by uropathogenic Escherichia coli (UPEC) (Roberts et al., 1994, PMID: 7914834). These structures are essential virulence factors that facilitate the colonization of the upper urinary tract by binding specifically to α-D-galactopyranosyl-(1-4)-β-D-galactopyranoside (galabiose) motifs found on the P-blood group antigen of human uroepithelial cells (Dodson et al., 2001, PMID: 11452310). The binding is mediated by the PapG adhesin, a lectin-like protein located at the distal tip of the fimbrial shaft (UniProt: P06746). This attachment allows the bacteria to resist the shearing forces of urine flow, promoting tissue invasion and the development of acute pyelonephritis. Because P-fimbriae are critical for the initiation of infection, they are significant targets for anti-adhesion therapies. Such therapies include galabioside mimetics and pilicides, which aim to prevent infection without the selective pressure of traditional antibiotics (Pinkner et al., 2006, PMID: 16763154). Research into these inhibitors focuses on reducing the incidence of recurrent urinary tract infections and preventing urosepsis. These agents represent a promising non-antibiotic approach to managing bacterial infections by targeting specific colonization mechanisms.
Competitive inhibition of the PapG adhesin binding to host cell galabiose receptors, preventing bacterial attachment and colonization (Dodson et al., 2001, PMID: 11452310). Pilicides specifically interfere with the chaperone-usher pathway required for fimbrial assembly (Pinkner et al., 2006, PMID: 16763154).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pyelonephritis-associated fimbriae (P-fimbriae) (P-fimbriae).